GLP-1 Perioperative Guide: Pre-Surgical Hold Protocols and Anesthesia Safety
Clinical guide for managing GLP-1 medications around surgery. ASA guidelines, hold timelines, aspiration risk, and resumption protocols for semaglutide, tirzepatide, and retatrutide.
More on Provider-Facing
Critical Safety Information
GLP-1 agonists delay gastric emptying, increasing aspiration risk during general anesthesia. ASA recommends holding weekly formulations at least 7 days before elective procedures. Consider gastric ultrasound for incompletely fasted patients.
Pre-Operative Protocol
Weekly GLP-1 (Semaglutide, Tirzepatide)
Hold for minimum 7 days before elective procedure requiring sedation or general anesthesia. For higher doses (semaglutide 2.4mg, tirzepatide 10-15mg), consider 2-3 week hold due to longer receptor occupancy and delayed gastric emptying duration. Document last injection date in pre-op assessment.
Day of Surgery Assessment
Confirm last GLP-1 dose date and time. Assess for active GI symptoms (nausea, bloating, reflux). Consider point-of-care gastric ultrasound if: held less than 7 days, on high doses, or reports GI symptoms. If significant gastric volume present: RSI, case delay, or cancellation as clinically appropriate.
Procedures NOT Requiring Hold
Office procedures with local anesthesia only do not require GLP-1 hold. Procedures under moderate sedation: use clinical judgment based on aspiration risk. Dental procedures under local: no hold needed. Document GLP-1 status in all pre-procedural assessments.
Post-Operative Resumption
Resumption Criteria
- Tolerating oral intake without nausea
- Bowel function returned
- No concurrent opioid-induced gastroparesis
- Surgical team clearance
Dosing After Hold
- Hold <4 weeks: resume at pre-hold dose
- Hold 4-8 weeks: restart one dose step lower
- Hold >8 weeks: restart at initial titration dose
- Monitor for side effect recurrence at resumption
Emergency Surgery Considerations
For emergent/urgent surgery in patients on active GLP-1 therapy: treat as full stomach regardless of NPO duration. Perform rapid sequence intubation. Consider gastric decompression with OG/NG tube. Document GLP-1 use prominently in anesthesia record. Post-operatively, hold GLP-1 until patient meets standard resumption criteria.
Clinical Disclaimer: This guide reflects ASA 2023 consensus guidance and may be updated. Verify current institutional protocols. Clinical judgment supersedes algorithmic recommendations.
Frequently Asked Questions
When should GLP-1 medications be held before surgery?
Per ASA 2023 guidelines: hold weekly GLP-1 medications (semaglutide, tirzepatide) for at least 7 days before elective surgery requiring general anesthesia. Daily formulations should be held 24 hours prior. Consider 2-3 week hold for patients on higher doses or those with significant GI symptoms.
What is the aspiration risk with GLP-1 medications?
GLP-1 agonists delay gastric emptying, potentially leaving residual gastric contents despite standard NPO fasting. This increases pulmonary aspiration risk during intubation. Case reports document full stomachs in GLP-1 patients who followed standard fasting protocols. Point-of-care gastric ultrasound can assess residual volume.
Should I use gastric ultrasound before intubation for GLP-1 patients?
Consider point-of-care gastric ultrasound for GLP-1 patients, especially those who held medication less than 7 days prior, are on higher doses, or report active GI symptoms. If significant gastric volume detected, consider rapid sequence intubation or case delay.
When can patients resume GLP-1 after surgery?
Resume when patient tolerates oral intake without nausea/vomiting, typically 1-3 days for minor procedures, 1-2 weeks for major surgery. Restart at the dose held (no re-titration needed for holds under 4 weeks). If held more than 4 weeks, consider restarting at a lower dose.
Trimi Provider Resources
Compounded semaglutide from $99/mo or tirzepatide from $125/mo.
View Treatment OptionsMedical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).